Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 190 across all filing types
Latest filing 2025-04-30 Annual Report
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
2024 ANNUAL REPORT
Annual Report Classification · 1% confidence The document is clearly identified as an 'Annual Report 2024' for CANbridge Pharmaceuticals Inc. It contains comprehensive sections including financial highlights, management discussion and analysis, corporate governance, and audited financial statements. It meets the criteria for a full annual report rather than an announcement or summary. FY 2024
2025-04-30 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025
Regulatory Filings Classification · 1% confidence The document is a Hong Kong Exchange Listing Rule FF301 monthly return filing, detailing movements in authorised share capital, issued shares, share options, warrants, convertibles, and other arrangements. It is a mandatory periodic regulatory submission to the HKEX rather than a management report, earnings release, or specific transaction announcement. It does not announce a one-time share issue, buyback, dividend, or AGM materials but serves as a routine regulatory filing under Chapter 19B. Therefore, it best fits the “Regulatory Filings” fallback category (RNS).
2025-04-03 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Regulatory Filings
2025-03-31 English
POSTPONEMENT OF DATE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a formal announcement under Hong Kong exchange rules notifying a change in the scheduled date of a board meeting to approve annual results. It does not itself contain financial results, vote tallies, managerial changes, or the report, nor is it the report itself. This type of miscellaneous regulatory announcement falls under the fallback category “Regulatory Filings” (RNS).
2025-03-27 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a brief announcement notifying shareholders of the date of the Board meeting to consider and approve the annual results. It does not contain the results themselves, nor changes to board composition, nor an actual financial report. It is a general regulatory announcement. The closest category is the fallback “Regulatory Filings” (RNS).
2025-03-18 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025
Regulatory Filings Classification · 1% confidence The document is a monthly regulatory return (Form FF301) submitted by an HKEX-listed issuer detailing movements in authorised share capital, issued shares, share options, and related confirmations under Chapter 19B of the Listing Rules. It is neither a financial report (Annual/Interim), earnings release, nor a specific corporate action notice like dividend or M&A. This monthly share movement return is a compliance/regulatory filing, best categorized under the general Regulatory Filings (RNS) fallback category.
2025-03-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.